A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Recursion Pharmaceuticals Inc’s current trading price is -55.62% away from its 52-week high, while its distance from the 52-week low is 44.72%. The stock’s price range for this time frame has been between $3.79 and $12.36. The trading volume of the company’s shares in the Healthcare reached around 10.39 million for the day, which was evidently lower than the average daily volume of 27.88 million over the last three months.
Recursion Pharmaceuticals Inc (RXRX) current stock price is $5.49. During the last trading session, the stock soared, reaching $10.0 after opening at $5.5. The stock’s lowest point was $3.0 before it closed at $5.36.
The stock market performance of Recursion Pharmaceuticals Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $12.36 on 02/18/25, while the lowest price during the same time frame was $3.79, recorded on 04/09/25.
How Financial Performance Impacts Market Capitalization
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly rise of 26.67% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.38B.
Decoding Analysts’ Ratings for Recursion Pharmaceuticals Inc
As of right now, 1 analyst is rating Recursion Pharmaceuticals Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.25, with a change in price of -0.96. Similarly, Recursion Pharmaceuticals Inc recorded 25,312,586 in trading volume during the last 100 days, posting a change of -15.02%.
How RXRX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.07.
RXRX Stock Stochastic Average
Recursion Pharmaceuticals Inc’s raw stochastic average for the past 50 days is currently at 43.42%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 14.85%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 13.37% and 14.85%, respectively.
RXRX Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Until today this year the stock’s price performance recorded a decrease of -13.89%. However, over the last six months, the performance has been stronger by -26.77%. The price of RXRX increased 3.88% over the last 30 days. And in the last five days, it has fallen by -5.43%.
